Alix Simon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alix Simon has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Agnès Ribes
INSERM, UMR1297 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
1 shared publication - Céline Tard
Centre de référence des maladies neuromusculaires Nord/Est/Île-de-France, CHU de Lille
1 shared publication - Jocelyn Laporte
Department of Translational Medicine IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), Inserm U1258, CNRS UMR7104, University of Strasbourg Illkirch France
1 shared publication - Johann Böhm
IGBMC (Institut de Génétique et de Biologie Moléculaire et Cellulaire), Inserm U1258, CNRS UMR7104, Université de Strasbourg, 67404 Illkirch, France
1 shared publication - Laura Pérez-Guàrdia
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Inserm U1258, CNRS UMR7104, Université de Strasbourg, 67404 Illkirch, France
1 shared publication - Lorenzo Silva-Hernandez
Neuromuscular Unit, Puerta de Hierro University Hospital of Majadahonda, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
ORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome
Tubular aggregate myopathy (TAM) and Stormorken syndrome (STRMK) are clinically overlapping disorders characterized by childhood-onset muscle weakness and a variable occurrence of multisystemic signs, including short stature, thrombocytopenia, and hyposplenism. TAM/STRMK is caused by gain-of-function mutations in the Ca 2+ sensor STIM1 or the Ca 2+ channel ORAI1, both of which regulate Ca 2+ homeostasis through the ubiquitous store-operated Ca 2+ entry (SOCE) mechanism. Functional experiments in cells have demonstrated that the TAM/STRMK mutations induce SOCE overactivation, resulting in excessive influx of extracellular Ca 2+ . There is currently no treatment for TAM/STRMK, but SOCE is amenable to manipulation. Here, we crossed Stim1 R304W/+ mice harboring the most common TAM/STRMK mutation with Orai1 R93W/+ mice carrying an ORAI1 mutation partially obstructing Ca 2+ influx. Compared with Stim1 R304W/+ littermates, Stim1 R304W/+ Orai1 R93W/+ offspring showed a normalization of bone architecture, spleen histology, and muscle morphology; an increase of thrombocytes; and improved muscle contraction and relaxation kinetics. Accordingly, comparative RNA-Seq detected more than 1,200 dysregulated genes in Stim1 R304W/+ muscle and revealed a major restoration of gene expression in Stim1 R304W/+ Orai1 R93W/+ mice. Altogether, we provide physiological, morphological, functional, and molecular data highlighting the therapeutic potential of ORAI1 inhibition to rescue the multisystemic TAM/STRMK signs, and we identified myostatin as a promising biomarker for TAM/STRMK in humans and mice.
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
Open AccessORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome
Tubular aggregate myopathy (TAM) and Stormorken syndrome (STRMK) are clinically overlapping disorders characterized by childhood-onset muscle weakness and a variable occurrence of multisystemic signs, including short stature, thrombocytopenia, and hyposplenism. TAM/STRMK is caused by gain-of-function mutations in the Ca 2+ sensor STIM1 or the Ca 2+ channel ORAI1, both of which regulate Ca 2+ homeostasis through the ubiquitous store-operated Ca 2+ entry (SOCE) mechanism. Functional experiments in cells have demonstrated that the TAM/STRMK mutations induce SOCE overactivation, resulting in excessive influx of extracellular Ca 2+ . There is currently no treatment for TAM/STRMK, but SOCE is amenable to manipulation. Here, we crossed Stim1 R304W/+ mice harboring the most common TAM/STRMK mutation with Orai1 R93W/+ mice carrying an ORAI1 mutation partially obstructing Ca 2+ influx. Compared with Stim1 R304W/+ littermates, Stim1 R304W/+ Orai1 R93W/+ offspring showed a normalization of bone architecture, spleen histology, and muscle morphology; an increase of thrombocytes; and improved muscle contraction and relaxation kinetics. Accordingly, comparative RNA-Seq detected more than 1,200 dysregulated genes in Stim1 R304W/+ muscle and revealed a major restoration of gene expression in Stim1 R304W/+ Orai1 R93W/+ mice. Altogether, we provide physiological, morphological, functional, and molecular data highlighting the therapeutic potential of ORAI1 inhibition to rescue the multisystemic TAM/STRMK signs, and we identified myostatin as a promising biomarker for TAM/STRMK in humans and mice.
- Open Access
- 17 November 2023
- Published by EDP Sciences in médecine/sciences
- Vol. 39, 22-27
Les omiques au service de la myologie
Malgré les efforts de la recherche biomédicale, les mécanismes pathologiques et les cibles thérapeutiques des maladies restent difficiles à identifier. L’essor des technologies à haut débit a conduit au développement de technologies innovantes dites « omiques » (omics en langue anglaise). Elles visent à caractériser de manière exhaustive un ensemble de molécules : gènes, ARN, protéines, métabolites, etc. Ces méthodes sans a priori permettent une caractérisation moléculaire fine des maladies et une meilleure compréhension des mécanismes physiopathologiques complexes. Dans cet article, nous ferons un tour d’horizon des approches omiques, de leur intégration et de leurs applications dans le contexte de la myologie. Despite efforts in biomedical research, pathophysiological mechanisms and therapeutic targets of diseases remain difficult to identify. The development of high-throughput techniques led to the advent of innovatve technologies called omics. They aim at characterizing as exhaustively as possible a set of molecules: genes, RNAs, proteins, metabolites, etc. These a priori methods allow a precise molecular characterization of diseases and a better understanding of complex pathophysiological mechanisms. In this paper, we will review most omics approaches, their integration and their applications in the context of myology.
- 17 November 2023
- Published by EDP Sciences in médecine/sciences
- Vol. 39, 22-27
Open AccessLes omiques au service de la myologie
Malgré les efforts de la recherche biomédicale, les mécanismes pathologiques et les cibles thérapeutiques des maladies restent difficiles à identifier. L’essor des technologies à haut débit a conduit au développement de technologies innovantes dites « omiques » (omics en langue anglaise). Elles visent à caractériser de manière exhaustive un ensemble de molécules : gènes, ARN, protéines, métabolites, etc. Ces méthodes sans a priori permettent une caractérisation moléculaire fine des maladies et une meilleure compréhension des mécanismes physiopathologiques complexes. Dans cet article, nous ferons un tour d’horizon des approches omiques, de leur intégration et de leurs applications dans le contexte de la myologie. Despite efforts in biomedical research, pathophysiological mechanisms and therapeutic targets of diseases remain difficult to identify. The development of high-throughput techniques led to the advent of innovatve technologies called omics. They aim at characterizing as exhaustively as possible a set of molecules: genes, RNAs, proteins, metabolites, etc. These a priori methods allow a precise molecular characterization of diseases and a better understanding of complex pathophysiological mechanisms. In this paper, we will review most omics approaches, their integration and their applications in the context of myology.